Cybin announces up to us$64 million offering of units

Toronto--(business wire)--cybin inc. (nyse american:cybn) (neo:cybn) (“cybin” or the “company”), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative next-generation psychedelic treatment options, is pleased to announce a firm commitment underwritten offering (the “offering”) of 66,666,667 units of the company (the “units”) to one of the company's largest existing institutional shareholders and new institutional investors at.
CYBN Ratings Summary
CYBN Quant Ranking